YB-1 Is Altered in Pregnancy-Associated Disorders and Affects Trophoblast in Vitro Properties via Alternation of Multiple Molecular Traits.
Abortion, Spontaneous
/ genetics
Adult
Apoptosis
Case-Control Studies
Cell Line
Cell Movement
Cell Proliferation
Down-Regulation
Female
Fetal Growth Retardation
/ genetics
Gene Knockdown Techniques
Humans
In Vitro Techniques
Male
NF-kappa B
/ metabolism
Pre-Eclampsia
/ genetics
Pregnancy
Pregnancy Complications
/ genetics
RNA, Messenger
/ genetics
Trophoblasts
/ metabolism
Up-Regulation
Y-Box-Binding Protein 1
/ antagonists & inhibitors
Young Adult
NF-κB
apoptosis
cold shock protein
intrauterine growth restriction
placentation
preeclampsia
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
05 Jul 2021
05 Jul 2021
Historique:
received:
04
06
2021
revised:
28
06
2021
accepted:
28
06
2021
entrez:
20
7
2021
pubmed:
21
7
2021
medline:
27
7
2021
Statut:
epublish
Résumé
Cold shock Y-box binding protein-1 (YB-1) coordinates several molecular processes between the nucleus and the cytoplasm and plays a crucial role in cell function. Moreover, it is involved in cancer progression, invasion, and metastasis. As trophoblast cells share similar characteristics with cancer cells, we hypothesized that YB-1 might also be necessary for trophoblast functionality. In samples of patients with intrauterine growth restriction, YB-1 mRNA levels were decreased, while they were increased in preeclampsia and unchanged in spontaneous abortions when compared to normal pregnant controls. Studies with overexpression and downregulation of YB-1 were performed to assess the key trophoblast processes in two trophoblast cell lines HTR8/SVneo and JEG3. Overexpression of YB-1 or exposure of trophoblast cells to recombinant YB-1 caused enhanced proliferation, while knockdown of YB-1 lead to proliferative disadvantage in JEG3 or HTR8/SVneo cells. The invasion and migration properties were affected at different degrees among the trophoblast cell lines. Trophoblast expression of genes mediating migration, invasion, apoptosis, and inflammation was altered upon YB-1 downregulation. Moreover, IL-6 secretion was excessively increased in HTR8/SVneo. Ultimately, YB-1 directly binds to NF-κB enhancer mark in HTR8/SVneo cells. Our data show that YB-1 protein is important for trophoblast cell functioning and, when downregulated, leads to trophoblast disadvantage that at least in part is mediated by NF-κB.
Identifiants
pubmed: 34281280
pii: ijms22137226
doi: 10.3390/ijms22137226
pmc: PMC8269420
pii:
doi:
Substances chimiques
NF-kappa B
0
RNA, Messenger
0
Y-Box-Binding Protein 1
0
YBX1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : ZE 526/14-1)
Références
Front Cell Dev Biol. 2019 Oct 01;7:221
pubmed: 31632972
J Biol Chem. 2006 Dec 29;281(52):40440-9
pubmed: 17082189
Am J Reprod Immunol. 2000 Jul;44(1):22-9
pubmed: 10976809
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
J Biol Chem. 2009 Sep 25;284(39):26928-40
pubmed: 19640841
J Clin Invest. 2003 Mar;111(5):649-58
pubmed: 12618519
Cancers (Basel). 2020 Aug 18;12(8):
pubmed: 32824741
Cells. 2020 Aug 22;9(9):
pubmed: 32842598
J Soc Gynecol Investig. 2004 Sep;11(6):342-52
pubmed: 15350246
Am J Reprod Immunol. 1998 Jan;39(1):41-9
pubmed: 9458933
Cancers (Basel). 2020 Aug 05;12(8):
pubmed: 32764479
EMBO Rep. 2009 Jul;10(7):783-9
pubmed: 19483673
Mol Hum Reprod. 2013 Aug;19(8):528-38
pubmed: 23538947
Br J Cancer. 2013 Mar 5;108(4):836-47
pubmed: 23462806
Placenta. 2002 Apr;23(4):257-73
pubmed: 11969336
Anticancer Res. 2017 Apr;37(4):1603-1608
pubmed: 28373420
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21931-6
pubmed: 21106759
Mol Med Rep. 2017 Jan;15(1):240-248
pubmed: 27922666
Biochem J. 2013 Jan 1;449(1):11-23
pubmed: 23216250
Mol Cell Biol. 2005 Jun;25(11):4625-37
pubmed: 15899865
Oncotarget. 2015 May 30;6(15):13718-30
pubmed: 25980435
Biol Reprod. 2010 Feb;82(2):235-45
pubmed: 19571263
Placenta. 2010 Jun;31(6):465-74
pubmed: 20359743
Best Pract Res Clin Obstet Gynaecol. 2011 Jun;25(3):313-27
pubmed: 21388889
Nucleic Acids Res. 1994 Jun 11;22(11):2036-41
pubmed: 8029009
J Virol. 1999 Dec;73(12):10146-57
pubmed: 10559330
Cell. 1989 Jul 28;58(2):227-9
pubmed: 2665943
Nat Med. 2006 Jun;12(6):642-9
pubmed: 16751767
Future Oncol. 2009 Mar;5(2):153-6
pubmed: 19284373
Oncotarget. 2016 Dec 13;7(50):82139-82157
pubmed: 27384875
J Clin Invest. 2007 Dec;117(12):3988-4002
pubmed: 18060036
Lab Invest. 2016 Apr;96(4):428-38
pubmed: 26752743
Endocr Rev. 2005 Dec;26(7):877-97
pubmed: 15901666
Oncogene. 2011 Aug 25;30(34):3649-60
pubmed: 21423216
J Clin Oncol. 2007 Apr 1;25(10):1196-208
pubmed: 17401009
Am J Obstet Gynecol. 2006 Apr;194(4):921-31
pubmed: 16580277
Int J Mol Sci. 2020 Mar 05;21(5):
pubmed: 32150832
Nucleic Acids Res. 2001 Mar 1;29(5):1200-7
pubmed: 11222770
Sci Rep. 2020 Aug 20;10(1):14033
pubmed: 32820194
BMC Cancer. 2020 Oct 14;20(1):996
pubmed: 33054752
Placenta. 1999 Jul-Aug;20(5-6):407-22
pubmed: 10419806
Cancer Sci. 2019 Jan;110(1):166-179
pubmed: 30426615
J Reprod Immunol. 2002 Jan;53(1-2):257-68
pubmed: 11730921
Am J Obstet Gynecol. 2015 Oct;213(4 Suppl):S115-22
pubmed: 26428489
Biochem Biophys Res Commun. 2010 Jul 30;398(3):482-8
pubmed: 20599698
Cell Mol Immunol. 2012 Mar;9(2):155-62
pubmed: 21983868
Cardiovasc Res. 2010 May 1;86(2):211-8
pubmed: 20202975
J Biol Chem. 2017 Feb 24;292(8):3433-3444
pubmed: 28077578
Biol Chem. 2005 Sep;386(9):865-72
pubmed: 16164411
BJOG. 2018 Oct;125(11):1379-1387
pubmed: 29460466
Am J Obstet Gynecol. 2002 Jan;186(1):158-66
pubmed: 11810103
Front Immunol. 2019 Dec 10;10:2896
pubmed: 31921157
Reproduction. 2016 Jul;152(1):11-22
pubmed: 27256632
Cell Commun Signal. 2018 Sep 26;16(1):63
pubmed: 30257675
Hum Reprod Update. 2007 Mar-Apr;13(2):121-41
pubmed: 17068222
Placenta. 2017 Feb;50:1-7
pubmed: 28161053